24
Views
15
CrossRef citations to date
0
Altmetric
Original Article

Successful Interferon-γ Therapy in a Chronic Granulomatous Disease (CGD) Patient Suffering from Staphylococcus aureus Hepatic Abscess and Invasive Candida albicans Infection

&
Pages 61-66 | Published online: 07 Feb 2010
 

Abstract

A 16-year old boy with an early history of recurrent lower respiratory tract infections exhibited symtoms of prolonged septic fever and liver abscess. Cultures from liver puncture were positive for Staphylococcus aureus, and the patient initially responded to antibacterial therapy. After a period of 4 months, however, the infection relapsed, and further treatment with broad antibacterial, antifungal and tuberculostatic drugs was ineffective. Neither soluble nor particulate stimuli were found to elicit the respiratory burst response in granulocytes from the patient. Spectral analysis of granulocyte cytochrome-b confirmed the diagnosis of chronic granulomatous disease. Since the patient's physical condition deteriorated severely during the prolonged (10-week) septic course, immunosupportive interferon-γ was added to the antimicrobial therapy. With this regime, the fever subsided and the general condition of the patient improved dramatically. He could be discharged from hospital 9 weeks after the introduction of interferon-γ and was, at an elective follow-up control 1 month later, convalescing and showed no signs of active infection.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.